Protalix Biotherapeutics, Inc. PLX 深 滬
等待開盤 07-18 09:30:00 美东时间
1.50
+0.070
+4.90%
華盛通- 最 高1.51
- 今 開1.47
- 成交量 68.43万股
- 最 低 1.45
- 昨 收 1.43
- 總市值 1.19亿
- 52周最高 3.10
- 市盈率 靜 40.98
- 換手率 0.86%
- 52周最低 0.8214
- 委 比 -33.33%
- 總股本 7960.71万
- 歷史最高 77.00
- 量 比 0.96
- 振 幅 4.20%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PLUXEE N.V. (PLX) Receives a Buy from Kepler Capital
In a report released on July 2, Julien Richer from Kepler Capital maintained a ...
07-04 09:36
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
CARMIEL, Israel, June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization o...
06-30 18:50
Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.
Protalix BioTherapeutics shares are trading lower after the company reported wo...
05-09 20:45
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 79.5% to $0.4...
05-09 20:10
Protalix BioTherapeutics Q1 EPS $(0.05) Misses $0.03 Estimate, Sales $10.11M Miss $21.60M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.03 by 266.67 percent. This is a 16.67 percent increase over losses of $(0.06) per share
05-09 18:53
Earnings Scheduled For May 9, 2025
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to ...
05-09 16:32
Protalix BioTherapeutics Q1 Earnings Preview
Protalix BioTherapeutics (NYSE:PLX) is scheduled to announce Q1 earnings results on Friday, May 9th, before market open. The consensus EPS Estimate is $0.08 (+233.3% Y/Y) and the consensus Revenue Est...
05-09 00:54
Protalix CFO Eyal Rubin Announces Resignation
An update from Protalix ( ($PLX) ) is now available. On April 21, 2025, Eyal Ru...
04-24 05:01
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge
Protalix Biotherapeutics ($PLX) has gained investor’s attention, and reported a...
03-20 09:55
Butterfly Network Is 'Pioneering Digital Ultrasound Market,' Analyst Says Undervalued Stock Could Rise With Growth Execution
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential and a growing ultrasound market.
03-18 02:25
